Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorPeng Liang

About this trial

The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:

* Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine? * How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.

Participants will:

* Receive either mivacurium chloride (0.14 mg/kg induction bolus + 0.5 mg/kg/h maintenance infusion) or succinylcholine (1 mg/kg induction bolus + 5 mg/kg/h maintenance infusion) as a muscle relaxant during bronchoscopy. * Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure. * Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.

Eligibility criteria

Qualifiers

Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.

Aged between 18 and 60 years.

Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.

Patients voluntarily participate and sign an informed consent form.

Disqualifiers

Patients with known allergies to any of the drugs involved in the study.

Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.

Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.

Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.

Trial design

Treatments tested in this trial

  • mivacurium chloride
  • succinylcholine

Treatment groups

240 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Peng Liang

Lead sponsor

West China Hospital

Sponsor institution